Evidence map›Paper›PMID 24104967›Full record

ArticleBritish journal of cancer2013

Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents.

G He, J Kuang, J Koomen, R Kobayashi, A R Khokhar, Z H Siddik

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

G HeDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 1950, 1515 Holcombe Boulevard, Houston, TX, USA.
J Kuang
J Koomen
R Kobayashi
A R Khokhar
Z H Siddik
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeted Development of Platinum DrugsR01CA160687 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SIDDIK, ZAHID H · 2011 to 2015
$1.6M
Checkpoint Response and Platinum Drug SensitivityR01CA127263 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SIDDIK, ZAHID H · 2007 to 2011
$1.3M
NCI NIH HHS CA127263NCI NIH HHS CA160687NCI NIH HHS CA16672NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA127263NCI NIH HHS R01 CA160687
6 · The paper itself

Abstract

backgroundIn cycling tumour cells, the binary cyclin-dependent kinase Cdk4/cyclin D or Cdk2/cyclin E complex is inhibited by p21 following DNA damage to induce G1 cell-cycle arrest. However, it is not known whether other proteins are also recruited within Cdk complexes, or their role, and this was investigated.

methodsOvarian A2780 tumour cells were exposed to the platinum-based antitumour agent 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) (DAP), which preferentially induces G1 arrest in a p21-dependent manner. The Cdk complexes were analysed by gel filtration chromatography, immunoblot and mass spectrometry.

resultsThe active forms of Cdk4 and Cdk2 complexes in control tumour cells have a molecular size of ~140 kDa, which increased to ~290 kDa when inhibited following G1 checkpoint activation by DAP. Proteomic analysis identified Cdk, cyclin, p21 and proliferating cell nuclear antigen (PCNA) in the inhibited complex, and biochemical studies provided unequivocal evidence that the increase in ~150 kDa of the inhibited complex is consistent with p21-dependent recruitment of PCNA as a trimer, likely bound to three molecules of p21. Although p21 alone was sufficient to inhibit the Cdk complex, PCNA was critical for stabilising p21.

conclusionG1 Cdk complexes inhibited by p21 also recruit PCNA, which inhibits degradation and, thereby, prolongs activity of p21 within the complex.

Indexed as

DNA DamageAntineoplastic AgentsCell Cycle CheckpointsCyclin DCyclin-Dependent Kinase 2Cyclin-Dependent Kinase 4Cyclin EG1 PhaseHCT116 CellsHumansMCF-7 CellsOrganoplatinum CompoundsProliferating Cell Nuclear AntigenProteomicsTumor Cells, CulturedAntineoplastic AgentsCDK2 protein, humanCDK4 protein, humanCyclin DCyclin-Dependent Kinase 2Cyclin-Dependent Kinase 4Cyclin E(diaminocyclohexane)(diacetato)(dichloro)platinumOrganoplatinum CompoundsProliferating Cell Nuclear Antigen

Identifiers

PMID24104967
PMCPMC3817341
OpenAlexW2050067447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.